BACKGROUND: The incidence of pediatric hospitalizations for community-acquired pneumonia (CAP) has declined after the widespread use of the heptavalent pneumococcal conjugate vaccine. The national incidence of outpatient visits for CAP, however, is not well established. Although no pediatric CAP treatment guidelines are available, current data support narrow-spectrum antibiotics as the first-line treatment for most patients with CAP. OBJECTIVE: To estimate the incidence rates of outpatient CAP, examine time trends in antibiotics prescribed for CAP, and determine factors associated with broad-spectrum antibiotic prescribing for CAP. PATIENTS AND METHODS: The National Ambulatory and National Hospital Ambulatory Medical Care Surveys (1994-2007) were used to identify children aged 1 to 18 years with CAP using a validated algorithm. We determined age group-specific rates of outpatient CAP and examined trends in antibiotic prescribing for CAP. Data from 2006-2007 were used to study factors associated with broad-spectrum antibiotic prescribing. RESULTS: Overall, annual CAP visit rates ranged from 16.9 to 22.4 per 1000 population, with the highest rates occurring in children aged 1 to 5 years (range: 32.3-49.6 per 1000). Ambulatory CAP visit rates did not change between 1994 and 2007. Antibiotics commonly prescribed for CAP included macrolides (34% of patients overall), cephalosporins (22% overall), and penicillins (14% overall). Cephalosporin use increased significantly between 2000 and 2007 (P = .002). Increasing age, a visit to a nonemergency department office, and obtaining a radiograph or complete blood count were associated with broad-spectrum antibiotic prescribing. CONCLUSIONS: The incidence of pediatric ambulatory CAP visits has not changed significantly between 1994 and 2007, despite the introduction of heptavalent pneumococcal conjugate vaccine in 2000. Broad-spectrum antibiotics, particularly macrolides, were frequently prescribed despite evidence that they provide little benefit over penicillins.
BACKGROUND: The incidence of pediatric hospitalizations for community-acquired pneumonia (CAP) has declined after the widespread use of the heptavalent pneumococcal conjugate vaccine. The national incidence of outpatient visits for CAP, however, is not well established. Although no pediatric CAP treatment guidelines are available, current data support narrow-spectrum antibiotics as the first-line treatment for most patients with CAP. OBJECTIVE: To estimate the incidence rates of outpatient CAP, examine time trends in antibiotics prescribed for CAP, and determine factors associated with broad-spectrum antibiotic prescribing for CAP. PATIENTS AND METHODS: The National Ambulatory and National Hospital Ambulatory Medical Care Surveys (1994-2007) were used to identify children aged 1 to 18 years with CAP using a validated algorithm. We determined age group-specific rates of outpatient CAP and examined trends in antibiotic prescribing for CAP. Data from 2006-2007 were used to study factors associated with broad-spectrum antibiotic prescribing. RESULTS: Overall, annual CAP visit rates ranged from 16.9 to 22.4 per 1000 population, with the highest rates occurring in children aged 1 to 5 years (range: 32.3-49.6 per 1000). Ambulatory CAP visit rates did not change between 1994 and 2007. Antibiotics commonly prescribed for CAP included macrolides (34% of patients overall), cephalosporins (22% overall), and penicillins (14% overall). Cephalosporin use increased significantly between 2000 and 2007 (P = .002). Increasing age, a visit to a nonemergency department office, and obtaining a radiograph or complete blood count were associated with broad-spectrum antibiotic prescribing. CONCLUSIONS: The incidence of pediatric ambulatory CAP visits has not changed significantly between 1994 and 2007, despite the introduction of heptavalent pneumococcal conjugate vaccine in 2000. Broad-spectrum antibiotics, particularly macrolides, were frequently prescribed despite evidence that they provide little benefit over penicillins.
Authors: Angela J Peck; Robert C Holman; Aaron T Curns; Jairam R Lingappa; James E Cheek; Rosalyn J Singleton; Karen Carver; Larry J Anderson Journal: Pediatr Infect Dis J Date: 2005-04 Impact factor: 2.129
Authors: Christopher J Stille; Susan E Andrade; Susan S Huang; James Nordin; Marsha A Raebel; Alan S Go; K Arnold Chan; Jonathan A Finkelstein Journal: Pediatrics Date: 2004-11 Impact factor: 7.124
Authors: Steven B Black; Henry R Shinefield; Stella Ling; John Hansen; Bruce Fireman; David Spring; Jack Noyes; Edwin Lewis; Paula Ray; Janelle Lee; Jill Hackell Journal: Pediatr Infect Dis J Date: 2002-09 Impact factor: 2.129
Authors: Ian C Michelow; Kurt Olsen; Juanita Lozano; Nancy K Rollins; Lynn B Duffy; Thedi Ziegler; Jaana Kauppila; Maija Leinonen; George H McCracken Journal: Pediatrics Date: 2004-04 Impact factor: 7.124
Authors: F Angoulvant; D Skurnik; H Bellanger; H Abdoul; X Bellettre; L Morin; M Aptecar; G Galli-Gibertini; O Bourdon; C Doit; A Faye; J-C Mercier; R Cohen; C Alberti Journal: Eur J Clin Microbiol Infect Dis Date: 2011-10-16 Impact factor: 3.267
Authors: Rachael K Ross; Adam L Hersh; Matthew P Kronman; Jason G Newland; Talene A Metjian; A Russell Localio; Theoklis E Zaoutis; Jeffrey S Gerber Journal: Clin Infect Dis Date: 2014-01-06 Impact factor: 9.079
Authors: Deverick J Anderson; Timothy C Jenkins; Scott R Evans; Anthony D Harris; Robert A Weinstein; Pranita D Tamma; Jennifer H Han; Ritu Banerjee; Robin Patel; Theoklis Zaoutis; Ebbing Lautenbach Journal: Clin Infect Dis Date: 2017-03-15 Impact factor: 9.079
Authors: Sharon K Greene; Kenneth P Kleinman; Matthew D Lakoma; Sheryl L Rifas-Shiman; Grace M Lee; Susan S Huang; Jonathan A Finkelstein Journal: Pediatrics Date: 2012-06-25 Impact factor: 7.124
Authors: Derek J Williams; Matthew Hall; Jeffrey S Gerber; Mark I Neuman; Adam L Hersh; Thomas V Brogan; Kavita Parikh; Sanjay Mahant; Anne J Blaschke; Samir S Shah; Carlos G Grijalva Journal: Pediatrics Date: 2017-03-08 Impact factor: 7.124